Beneficial	O
Effects	O
on	O
Pregnancy	B:C0032972
Outcomes	I:C0032972
of	O
Thyroid	O
Hormone	I:C2242640
Replacement	I:C2242640
for	O
Subclinical	O
Hypothyroidism	I:C0271790
.	O

Beneficial	O
Effects	O
on	O
Pregnancy	O
Outcomes	I:C0032972
of	O
Thyroid	B:C2242640
Hormone	I:C2242640
Replacement	I:C2242640
for	O
Subclinical	O
Hypothyroidism	I:C0271790
.	O

Beneficial	O
Effects	O
on	O
Pregnancy	O
Outcomes	I:C0032972
of	O
Thyroid	O
Hormone	I:C2242640
Replacement	I:C2242640
for	O
Subclinical	B:C0271790
Hypothyroidism	I:C0271790
.	O

Hypothyroidism	B:C0020676
and	O
raised	O
thyroid	O
antibody	I:C0700384
levels	O
have	O
been	O
associated	O
with	O
adverse	O
obstetrical	O
outcomes	I:C0206277
.	O

Hypothyroidism	O
and	O
raised	O
thyroid	B:C0700384
antibody	I:C0700384
levels	O
have	O
been	O
associated	O
with	O
adverse	O
obstetrical	O
outcomes	I:C0206277
.	O

Hypothyroidism	O
and	O
raised	O
thyroid	O
antibody	I:C0700384
levels	O
have	O
been	O
associated	O
with	O
adverse	B:C0559546
obstetrical	O
outcomes	I:C0206277
.	O

Hypothyroidism	O
and	O
raised	O
thyroid	O
antibody	I:C0700384
levels	O
have	O
been	O
associated	O
with	O
adverse	O
obstetrical	B:C0206277
outcomes	I:C0206277
.	O

Several	O
studies	B:C2603343
have	O
investigated	O
causal	O
associations	O
,	O
but	O
results	O
have	O
been	O
inconsistent	O
and	O
few	O
studies	O
have	O
reported	O
the	O
effects	O
of	O
thyroxine	O
replacement	I:C2242640
therapy	I:C2242640
on	O
pregnancy	O
outcomes	I:C0032972
in	O
hypothyroid	O
patients	O
.	O

Several	O
studies	O
have	O
investigated	O
causal	O
associations	O
,	O
but	O
results	O
have	O
been	O
inconsistent	O
and	O
few	O
studies	B:C2603343
have	O
reported	O
the	O
effects	O
of	O
thyroxine	O
replacement	I:C2242640
therapy	I:C2242640
on	O
pregnancy	O
outcomes	I:C0032972
in	O
hypothyroid	O
patients	O
.	O

Several	O
studies	O
have	O
investigated	O
causal	O
associations	O
,	O
but	O
results	O
have	O
been	O
inconsistent	O
and	O
few	O
studies	O
have	O
reported	O
the	O
effects	O
of	O
thyroxine	B:C2242640
replacement	I:C2242640
therapy	I:C2242640
on	O
pregnancy	O
outcomes	I:C0032972
in	O
hypothyroid	O
patients	O
.	O

Several	O
studies	O
have	O
investigated	O
causal	O
associations	O
,	O
but	O
results	O
have	O
been	O
inconsistent	O
and	O
few	O
studies	O
have	O
reported	O
the	O
effects	O
of	O
thyroxine	O
replacement	I:C2242640
therapy	I:C2242640
on	O
pregnancy	B:C0032972
outcomes	I:C0032972
in	O
hypothyroid	O
patients	O
.	O

Several	O
studies	O
have	O
investigated	O
causal	O
associations	O
,	O
but	O
results	O
have	O
been	O
inconsistent	O
and	O
few	O
studies	O
have	O
reported	O
the	O
effects	O
of	O
thyroxine	O
replacement	I:C2242640
therapy	I:C2242640
on	O
pregnancy	O
outcomes	I:C0032972
in	O
hypothyroid	B:C0020676
patients	O
.	O

The	O
primary	O
study	O
objective	O
was	O
to	O
determine	O
the	O
outcome	B:C0032972
of	I:C0032972
pregnancies	I:C0032972
in	O
women	O
diagnosed	O
with	O
overt	O
and	O
subclinical	O
hypothyroidism	I:C0271790
(	O
subclinical	O
hypothyroidism	I:C0271790
)	O
(	O
serum	O
TSH	I:C1277938
>	O
2.5	O
m	O
IU/L	O
)	O
and	O
those	O
with	O
elevated	O
circulating	O
thyroid	O
autoantibody	I:C0700384
levels	O
in	O
the	O
first	O
trimester	O
of	O
pregnancy	O
and	O
after	O
the	O
institution	O
of	O
appropriate	O
thyroxine	O
replacement	I:C2242640
therapy	I:C2242640
to	O
maintain	O
the	O
serum	O
TSH	I:C1277938
≤	O
2.5	O
mIU	O
/	O
L.	O
Study	O
Design	O
.	O

The	O
primary	O
study	O
objective	O
was	O
to	O
determine	O
the	O
outcome	O
of	I:C0032972
pregnancies	I:C0032972
in	O
women	B:C0043210
diagnosed	O
with	O
overt	O
and	O
subclinical	O
hypothyroidism	I:C0271790
(	O
subclinical	O
hypothyroidism	I:C0271790
)	O
(	O
serum	O
TSH	I:C1277938
>	O
2.5	O
m	O
IU/L	O
)	O
and	O
those	O
with	O
elevated	O
circulating	O
thyroid	O
autoantibody	I:C0700384
levels	O
in	O
the	O
first	O
trimester	O
of	O
pregnancy	O
and	O
after	O
the	O
institution	O
of	O
appropriate	O
thyroxine	O
replacement	I:C2242640
therapy	I:C2242640
to	O
maintain	O
the	O
serum	O
TSH	I:C1277938
≤	O
2.5	O
mIU	O
/	O
L.	O
Study	O
Design	O
.	O

The	O
primary	O
study	O
objective	O
was	O
to	O
determine	O
the	O
outcome	O
of	I:C0032972
pregnancies	I:C0032972
in	O
women	O
diagnosed	B:C0011900
with	O
overt	O
and	O
subclinical	O
hypothyroidism	I:C0271790
(	O
subclinical	O
hypothyroidism	I:C0271790
)	O
(	O
serum	O
TSH	I:C1277938
>	O
2.5	O
m	O
IU/L	O
)	O
and	O
those	O
with	O
elevated	O
circulating	O
thyroid	O
autoantibody	I:C0700384
levels	O
in	O
the	O
first	O
trimester	O
of	O
pregnancy	O
and	O
after	O
the	O
institution	O
of	O
appropriate	O
thyroxine	O
replacement	I:C2242640
therapy	I:C2242640
to	O
maintain	O
the	O
serum	O
TSH	I:C1277938
≤	O
2.5	O
mIU	O
/	O
L.	O
Study	O
Design	O
.	O

The	O
primary	O
study	O
objective	O
was	O
to	O
determine	O
the	O
outcome	O
of	I:C0032972
pregnancies	I:C0032972
in	O
women	O
diagnosed	O
with	O
overt	O
and	O
subclinical	B:C0271790
hypothyroidism	I:C0271790
(	O
subclinical	O
hypothyroidism	I:C0271790
)	O
(	O
serum	O
TSH	I:C1277938
>	O
2.5	O
m	O
IU/L	O
)	O
and	O
those	O
with	O
elevated	O
circulating	O
thyroid	O
autoantibody	I:C0700384
levels	O
in	O
the	O
first	O
trimester	O
of	O
pregnancy	O
and	O
after	O
the	O
institution	O
of	O
appropriate	O
thyroxine	O
replacement	I:C2242640
therapy	I:C2242640
to	O
maintain	O
the	O
serum	O
TSH	I:C1277938
≤	O
2.5	O
mIU	O
/	O
L.	O
Study	O
Design	O
.	O

The	O
primary	O
study	O
objective	O
was	O
to	O
determine	O
the	O
outcome	O
of	I:C0032972
pregnancies	I:C0032972
in	O
women	O
diagnosed	O
with	O
overt	O
and	O
subclinical	O
hypothyroidism	I:C0271790
(	O
subclinical	B:C0271790
hypothyroidism	I:C0271790
)	O
(	O
serum	O
TSH	I:C1277938
>	O
2.5	O
m	O
IU/L	O
)	O
and	O
those	O
with	O
elevated	O
circulating	O
thyroid	O
autoantibody	I:C0700384
levels	O
in	O
the	O
first	O
trimester	O
of	O
pregnancy	O
and	O
after	O
the	O
institution	O
of	O
appropriate	O
thyroxine	O
replacement	I:C2242640
therapy	I:C2242640
to	O
maintain	O
the	O
serum	O
TSH	I:C1277938
≤	O
2.5	O
mIU	O
/	O
L.	O
Study	O
Design	O
.	O

The	O
primary	O
study	O
objective	O
was	O
to	O
determine	O
the	O
outcome	O
of	I:C0032972
pregnancies	I:C0032972
in	O
women	O
diagnosed	O
with	O
overt	O
and	O
subclinical	O
hypothyroidism	I:C0271790
(	O
subclinical	O
hypothyroidism	I:C0271790
)	O
(	O
serum	B:C1277938
TSH	I:C1277938
>	O
2.5	O
m	O
IU/L	O
)	O
and	O
those	O
with	O
elevated	O
circulating	O
thyroid	O
autoantibody	I:C0700384
levels	O
in	O
the	O
first	O
trimester	O
of	O
pregnancy	O
and	O
after	O
the	O
institution	O
of	O
appropriate	O
thyroxine	O
replacement	I:C2242640
therapy	I:C2242640
to	O
maintain	O
the	O
serum	O
TSH	I:C1277938
≤	O
2.5	O
mIU	O
/	O
L.	O
Study	O
Design	O
.	O

The	O
primary	O
study	O
objective	O
was	O
to	O
determine	O
the	O
outcome	O
of	I:C0032972
pregnancies	I:C0032972
in	O
women	O
diagnosed	O
with	O
overt	O
and	O
subclinical	O
hypothyroidism	I:C0271790
(	O
subclinical	O
hypothyroidism	I:C0271790
)	O
(	O
serum	O
TSH	I:C1277938
>	O
2.5	O
m	O
IU/L	O
)	O
and	O
those	O
with	O
elevated	O
circulating	O
thyroid	B:C0700384
autoantibody	I:C0700384
levels	O
in	O
the	O
first	O
trimester	O
of	O
pregnancy	O
and	O
after	O
the	O
institution	O
of	O
appropriate	O
thyroxine	O
replacement	I:C2242640
therapy	I:C2242640
to	O
maintain	O
the	O
serum	O
TSH	I:C1277938
≤	O
2.5	O
mIU	O
/	O
L.	O
Study	O
Design	O
.	O

The	O
primary	O
study	O
objective	O
was	O
to	O
determine	O
the	O
outcome	O
of	I:C0032972
pregnancies	I:C0032972
in	O
women	O
diagnosed	O
with	O
overt	O
and	O
subclinical	O
hypothyroidism	I:C0271790
(	O
subclinical	O
hypothyroidism	I:C0271790
)	O
(	O
serum	O
TSH	I:C1277938
>	O
2.5	O
m	O
IU/L	O
)	O
and	O
those	O
with	O
elevated	O
circulating	O
thyroid	O
autoantibody	I:C0700384
levels	O
in	O
the	O
first	O
trimester	O
of	O
pregnancy	O
and	O
after	O
the	O
institution	O
of	O
appropriate	O
thyroxine	B:C2242640
replacement	I:C2242640
therapy	I:C2242640
to	O
maintain	O
the	O
serum	O
TSH	I:C1277938
≤	O
2.5	O
mIU	O
/	O
L.	O
Study	O
Design	O
.	O

The	O
primary	O
study	O
objective	O
was	O
to	O
determine	O
the	O
outcome	O
of	I:C0032972
pregnancies	I:C0032972
in	O
women	O
diagnosed	O
with	O
overt	O
and	O
subclinical	O
hypothyroidism	I:C0271790
(	O
subclinical	O
hypothyroidism	I:C0271790
)	O
(	O
serum	O
TSH	I:C1277938
>	O
2.5	O
m	O
IU/L	O
)	O
and	O
those	O
with	O
elevated	O
circulating	O
thyroid	O
autoantibody	I:C0700384
levels	O
in	O
the	O
first	O
trimester	O
of	O
pregnancy	O
and	O
after	O
the	O
institution	O
of	O
appropriate	O
thyroxine	O
replacement	I:C2242640
therapy	I:C2242640
to	O
maintain	O
the	O
serum	B:C1277938
TSH	I:C1277938
≤	O
2.5	O
mIU	O
/	O
L.	O
Study	O
Design	O
.	O

This	O
prospective	B:C0033522
observational	O
study	I:C1518527
was	O
undertaken	O
between	O
2013	O
and	O
2016	O
.	O

This	O
prospective	O
observational	B:C1518527
study	I:C1518527
was	O
undertaken	O
between	O
2013	O
and	O
2016	O
.	O

Blood	B:C0178913
samples	I:C0178913
were	O
taken	O
from	O
1025	O
women	O
at	O
presentation	O
for	O
thyroid	O
stimulating	I:C0040160
hormone	I:C0040160
(	O
thyroid	O
stimulating	I:C0040160
hormone	I:C0040160
)	O
,	O
anti-thyroglobulin	O
antibodies	I:C0443883
(	O
anti-	O
thyroglobulin	I:C0443883
antibodies	I:C0443883
)	O
,	O
and	O
thyroid	O
peroxidase	I:C0076635
antibodies	I:C0076635
(	O
thyroid	O
peroxidase	I:C0076635
antibodies	I:C0076635
)	O
.	O

Blood	O
samples	I:C0178913
were	O
taken	O
from	O
1025	O
women	B:C0043210
at	O
presentation	O
for	O
thyroid	O
stimulating	I:C0040160
hormone	I:C0040160
(	O
thyroid	O
stimulating	I:C0040160
hormone	I:C0040160
)	O
,	O
anti-thyroglobulin	O
antibodies	I:C0443883
(	O
anti-	O
thyroglobulin	I:C0443883
antibodies	I:C0443883
)	O
,	O
and	O
thyroid	O
peroxidase	I:C0076635
antibodies	I:C0076635
(	O
thyroid	O
peroxidase	I:C0076635
antibodies	I:C0076635
)	O
.	O

Blood	O
samples	I:C0178913
were	O
taken	O
from	O
1025	O
women	O
at	O
presentation	O
for	O
thyroid	B:C0040160
stimulating	I:C0040160
hormone	I:C0040160
(	O
thyroid	O
stimulating	I:C0040160
hormone	I:C0040160
)	O
,	O
anti-thyroglobulin	O
antibodies	I:C0443883
(	O
anti-	O
thyroglobulin	I:C0443883
antibodies	I:C0443883
)	O
,	O
and	O
thyroid	O
peroxidase	I:C0076635
antibodies	I:C0076635
(	O
thyroid	O
peroxidase	I:C0076635
antibodies	I:C0076635
)	O
.	O

Blood	O
samples	I:C0178913
were	O
taken	O
from	O
1025	O
women	O
at	O
presentation	O
for	O
thyroid	O
stimulating	I:C0040160
hormone	I:C0040160
(	O
thyroid	B:C0040160
stimulating	I:C0040160
hormone	I:C0040160
)	O
,	O
anti-thyroglobulin	O
antibodies	I:C0443883
(	O
anti-	O
thyroglobulin	I:C0443883
antibodies	I:C0443883
)	O
,	O
and	O
thyroid	O
peroxidase	I:C0076635
antibodies	I:C0076635
(	O
thyroid	O
peroxidase	I:C0076635
antibodies	I:C0076635
)	O
.	O

Blood	O
samples	I:C0178913
were	O
taken	O
from	O
1025	O
women	O
at	O
presentation	O
for	O
thyroid	O
stimulating	I:C0040160
hormone	I:C0040160
(	O
thyroid	O
stimulating	I:C0040160
hormone	I:C0040160
)	O
,	O
anti-thyroglobulin	B:C0443883
antibodies	I:C0443883
(	O
anti-	O
thyroglobulin	I:C0443883
antibodies	I:C0443883
)	O
,	O
and	O
thyroid	O
peroxidase	I:C0076635
antibodies	I:C0076635
(	O
thyroid	O
peroxidase	I:C0076635
antibodies	I:C0076635
)	O
.	O

Blood	O
samples	I:C0178913
were	O
taken	O
from	O
1025	O
women	O
at	O
presentation	O
for	O
thyroid	O
stimulating	I:C0040160
hormone	I:C0040160
(	O
thyroid	O
stimulating	I:C0040160
hormone	I:C0040160
)	O
,	O
anti-thyroglobulin	O
antibodies	I:C0443883
(	O
anti-	B:C0443883
thyroglobulin	I:C0443883
antibodies	I:C0443883
)	O
,	O
and	O
thyroid	O
peroxidase	I:C0076635
antibodies	I:C0076635
(	O
thyroid	O
peroxidase	I:C0076635
antibodies	I:C0076635
)	O
.	O

Blood	O
samples	I:C0178913
were	O
taken	O
from	O
1025	O
women	O
at	O
presentation	O
for	O
thyroid	O
stimulating	I:C0040160
hormone	I:C0040160
(	O
thyroid	O
stimulating	I:C0040160
hormone	I:C0040160
)	O
,	O
anti-thyroglobulin	O
antibodies	I:C0443883
(	O
anti-	O
thyroglobulin	I:C0443883
antibodies	I:C0443883
)	O
,	O
and	O
thyroid	B:C0076635
peroxidase	I:C0076635
antibodies	I:C0076635
(	O
thyroid	O
peroxidase	I:C0076635
antibodies	I:C0076635
)	O
.	O

Blood	O
samples	I:C0178913
were	O
taken	O
from	O
1025	O
women	O
at	O
presentation	O
for	O
thyroid	O
stimulating	I:C0040160
hormone	I:C0040160
(	O
thyroid	O
stimulating	I:C0040160
hormone	I:C0040160
)	O
,	O
anti-thyroglobulin	O
antibodies	I:C0443883
(	O
anti-	O
thyroglobulin	I:C0443883
antibodies	I:C0443883
)	O
,	O
and	O
thyroid	O
peroxidase	I:C0076635
antibodies	I:C0076635
(	O
thyroid	B:C0076635
peroxidase	I:C0076635
antibodies	I:C0076635
)	O
.	O

Those	O
with	O
a	O
thyroid	B:C0040160
stimulating	I:C0040160
hormone	I:C0040160
>	O
2.5	O
mIU/L	O
were	O
treated	O
with	I:C0332293
thyroxine	O
and	O
managed	O
appropriately	O
to	O
ensure	O
that	O
the	O
thyroid	O
stimulating	I:C0040160
hormone	I:C0040160
was	O
maintained	O
≤	O
2.5	O
mIU/	O
L.	O

Those	O
with	O
a	O
thyroid	O
stimulating	I:C0040160
hormone	I:C0040160
>	O
2.5	O
mIU/L	O
were	O
treated	B:C0332293
with	I:C0332293
thyroxine	O
and	O
managed	O
appropriately	O
to	O
ensure	O
that	O
the	O
thyroid	O
stimulating	I:C0040160
hormone	I:C0040160
was	O
maintained	O
≤	O
2.5	O
mIU/	O
L.	O

Those	O
with	O
a	O
thyroid	O
stimulating	I:C0040160
hormone	I:C0040160
>	O
2.5	O
mIU/L	O
were	O
treated	O
with	I:C0332293
thyroxine	B:C0040165
and	O
managed	O
appropriately	O
to	O
ensure	O
that	O
the	O
thyroid	O
stimulating	I:C0040160
hormone	I:C0040160
was	O
maintained	O
≤	O
2.5	O
mIU/	O
L.	O

Those	O
with	O
a	O
thyroid	O
stimulating	I:C0040160
hormone	I:C0040160
>	O
2.5	O
mIU/L	O
were	O
treated	O
with	I:C0332293
thyroxine	O
and	O
managed	O
appropriately	O
to	O
ensure	O
that	O
the	O
thyroid	B:C0040160
stimulating	I:C0040160
hormone	I:C0040160
was	O
maintained	O
≤	O
2.5	O
mIU/	O
L.	O

Outcomes	O
in	O
these	O
patients	O
were	O
compared	O
to	O
those	O
in	O
euthyroid	B:C0117002
patients	O
.	O

Maternal	O
antenatal	O
complications	B:C0009566
and	O
perinatal	O
outcomes	O
were	O
recorded	O
.	O

There	O
were	O
a	O
total	O
of	O
1025	O
patients	O
of	O
whom	O
382	O
(	O
37.5	O
%	O
)	O
were	O
nulliparous	B:C0425979
.	O

10.1	O
%	O
had	O
a	O
thyroid	B:C0040160
stimulating	I:C0040160
hormone	I:C0040160
level	O
>	O
2.5	O
mIU/L	O
and	O
18.2	O
%	O
had	O
at	O
least	O
one	O
raised	O
thyroid	O
antibody	I:C0700384
level	O
.	O

10.1	O
%	O
had	O
a	O
thyroid	O
stimulating	I:C0040160
hormone	I:C0040160
level	O
>	O
2.5	O
mIU/L	O
and	O
18.2	O
%	O
had	O
at	O
least	O
one	O
raised	O
thyroid	B:C0700384
antibody	I:C0700384
level	O
.	O

No	O
differences	O
in	O
adverse	B:C0559546
outcomes	O
of	I:C0032972
pregnancy	I:C0032972
were	O
evident	O
in	O
women	O
treated	O
for	O
subclinical	O
hypothyroidism	I:C0271790
or	O
overt	O
hypothyroidism	O
compared	O
to	O
the	O
euthyroid	O
group	O
.	O

No	O
differences	O
in	O
adverse	O
outcomes	B:C0032972
of	I:C0032972
pregnancy	I:C0032972
were	O
evident	O
in	O
women	O
treated	O
for	O
subclinical	O
hypothyroidism	I:C0271790
or	O
overt	O
hypothyroidism	O
compared	O
to	O
the	O
euthyroid	O
group	O
.	O

No	O
differences	O
in	O
adverse	O
outcomes	O
of	I:C0032972
pregnancy	I:C0032972
were	O
evident	O
in	O
women	B:C0043210
treated	O
for	O
subclinical	O
hypothyroidism	I:C0271790
or	O
overt	O
hypothyroidism	O
compared	O
to	O
the	O
euthyroid	O
group	O
.	O

No	O
differences	O
in	O
adverse	O
outcomes	O
of	I:C0032972
pregnancy	I:C0032972
were	O
evident	O
in	O
women	O
treated	O
for	O
subclinical	B:C0271790
hypothyroidism	I:C0271790
or	O
overt	O
hypothyroidism	O
compared	O
to	O
the	O
euthyroid	O
group	O
.	O

No	O
differences	O
in	O
adverse	O
outcomes	O
of	I:C0032972
pregnancy	I:C0032972
were	O
evident	O
in	O
women	O
treated	O
for	O
subclinical	O
hypothyroidism	I:C0271790
or	O
overt	O
hypothyroidism	B:C0020676
compared	O
to	O
the	O
euthyroid	O
group	O
.	O

No	O
differences	O
in	O
adverse	O
outcomes	O
of	I:C0032972
pregnancy	I:C0032972
were	O
evident	O
in	O
women	O
treated	O
for	O
subclinical	O
hypothyroidism	I:C0271790
or	O
overt	O
hypothyroidism	O
compared	O
to	O
the	O
euthyroid	B:C0117002
group	O
.	O

No	O
differences	O
in	O
adverse	O
outcomes	O
of	I:C0032972
pregnancy	I:C0032972
were	O
evident	O
in	O
women	O
treated	O
for	O
subclinical	O
hypothyroidism	I:C0271790
or	O
overt	O
hypothyroidism	O
compared	O
to	O
the	O
euthyroid	O
group	B:C1257890
.	O

There	O
was	O
also	O
no	O
association	O
between	O
raised	O
thyroid	B:C0700384
antibodies	I:C0700384
and	O
adverse	O
pregnancy	O
outcomes	I:C0032972
in	O
either	O
group	O
.	O

There	O
was	O
also	O
no	O
association	O
between	O
raised	O
thyroid	O
antibodies	I:C0700384
and	O
adverse	B:C0559546
pregnancy	O
outcomes	I:C0032972
in	O
either	O
group	O
.	O

There	O
was	O
also	O
no	O
association	O
between	O
raised	O
thyroid	O
antibodies	I:C0700384
and	O
adverse	O
pregnancy	B:C0032972
outcomes	I:C0032972
in	O
either	O
group	O
.	O

There	O
was	O
also	O
no	O
association	O
between	O
raised	O
thyroid	O
antibodies	I:C0700384
and	O
adverse	O
pregnancy	O
outcomes	I:C0032972
in	O
either	O
group	B:C1257890
.	O

There	O
were	O
no	O
adverse	B:C0559546
outcomes	O
of	I:C0032972
pregnancy	I:C0032972
found	O
in	O
pregnant	O
women	I:C0033011
who	O
had	O
been	O
diagnosed	O
and	O
treated	O
with	I:C0332293
thyroxine	O
for	O
subclinical	O
hypothyroidism	I:C0271790
at	O
the	O
time	O
of	O
presentation	O
when	O
compared	O
to	O
euthyroid	O
patients	O
.	O

There	O
were	O
no	O
adverse	O
outcomes	B:C0032972
of	I:C0032972
pregnancy	I:C0032972
found	O
in	O
pregnant	O
women	I:C0033011
who	O
had	O
been	O
diagnosed	O
and	O
treated	O
with	I:C0332293
thyroxine	O
for	O
subclinical	O
hypothyroidism	I:C0271790
at	O
the	O
time	O
of	O
presentation	O
when	O
compared	O
to	O
euthyroid	O
patients	O
.	O

There	O
were	O
no	O
adverse	O
outcomes	O
of	I:C0032972
pregnancy	I:C0032972
found	O
in	O
pregnant	B:C0033011
women	I:C0033011
who	O
had	O
been	O
diagnosed	O
and	O
treated	O
with	I:C0332293
thyroxine	O
for	O
subclinical	O
hypothyroidism	I:C0271790
at	O
the	O
time	O
of	O
presentation	O
when	O
compared	O
to	O
euthyroid	O
patients	O
.	O

There	O
were	O
no	O
adverse	O
outcomes	O
of	I:C0032972
pregnancy	I:C0032972
found	O
in	O
pregnant	O
women	I:C0033011
who	O
had	O
been	O
diagnosed	B:C0011900
and	O
treated	O
with	I:C0332293
thyroxine	O
for	O
subclinical	O
hypothyroidism	I:C0271790
at	O
the	O
time	O
of	O
presentation	O
when	O
compared	O
to	O
euthyroid	O
patients	O
.	O

There	O
were	O
no	O
adverse	O
outcomes	O
of	I:C0032972
pregnancy	I:C0032972
found	O
in	O
pregnant	O
women	I:C0033011
who	O
had	O
been	O
diagnosed	O
and	O
treated	B:C0332293
with	I:C0332293
thyroxine	O
for	O
subclinical	O
hypothyroidism	I:C0271790
at	O
the	O
time	O
of	O
presentation	O
when	O
compared	O
to	O
euthyroid	O
patients	O
.	O

There	O
were	O
no	O
adverse	O
outcomes	O
of	I:C0032972
pregnancy	I:C0032972
found	O
in	O
pregnant	O
women	I:C0033011
who	O
had	O
been	O
diagnosed	O
and	O
treated	O
with	I:C0332293
thyroxine	B:C0040165
for	O
subclinical	O
hypothyroidism	I:C0271790
at	O
the	O
time	O
of	O
presentation	O
when	O
compared	O
to	O
euthyroid	O
patients	O
.	O

There	O
were	O
no	O
adverse	O
outcomes	O
of	I:C0032972
pregnancy	I:C0032972
found	O
in	O
pregnant	O
women	I:C0033011
who	O
had	O
been	O
diagnosed	O
and	O
treated	O
with	I:C0332293
thyroxine	O
for	O
subclinical	B:C0271790
hypothyroidism	I:C0271790
at	O
the	O
time	O
of	O
presentation	O
when	O
compared	O
to	O
euthyroid	O
patients	O
.	O

There	O
were	O
no	O
adverse	O
outcomes	O
of	I:C0032972
pregnancy	I:C0032972
found	O
in	O
pregnant	O
women	I:C0033011
who	O
had	O
been	O
diagnosed	O
and	O
treated	O
with	I:C0332293
thyroxine	O
for	O
subclinical	O
hypothyroidism	I:C0271790
at	O
the	O
time	O
of	O
presentation	O
when	O
compared	O
to	O
euthyroid	B:C0117002
patients	O
.	O

There	O
was	O
also	O
no	O
relationship	O
with	O
thyroid	B:C0700384
antibodies	I:C0700384
and	O
adverse	O
pregnancy	O
outcomes	I:C0032972
in	O
the	O
two	O
groups	O
.	O

There	O
was	O
also	O
no	O
relationship	O
with	O
thyroid	O
antibodies	I:C0700384
and	O
adverse	B:C0559546
pregnancy	O
outcomes	I:C0032972
in	O
the	O
two	O
groups	O
.	O

There	O
was	O
also	O
no	O
relationship	O
with	O
thyroid	O
antibodies	I:C0700384
and	O
adverse	O
pregnancy	B:C0032972
outcomes	I:C0032972
in	O
the	O
two	O
groups	O
.	O

There	O
was	O
also	O
no	O
relationship	O
with	O
thyroid	O
antibodies	I:C0700384
and	O
adverse	O
pregnancy	O
outcomes	I:C0032972
in	O
the	O
two	O
groups	B:C1257890
.	O

It	O
is	O
not	O
possible	O
to	O
unequivocally	O
advocate	O
for	O
thyroxine	B:C0040165
replacement	O
in	O
pregnant	O
women	I:C0033011
with	O
subclinical	O
and	O
overt	O
hypothyroidism	O
until	O
large	O
scale	O
randomized	O
controlled	I:C0206035
trials	I:C0206035
are	O
performed	O
.	O

It	O
is	O
not	O
possible	O
to	O
unequivocally	O
advocate	O
for	O
thyroxine	O
replacement	O
in	O
pregnant	B:C0033011
women	I:C0033011
with	O
subclinical	O
and	O
overt	O
hypothyroidism	O
until	O
large	O
scale	O
randomized	O
controlled	I:C0206035
trials	I:C0206035
are	O
performed	O
.	O

It	O
is	O
not	O
possible	O
to	O
unequivocally	O
advocate	O
for	O
thyroxine	O
replacement	O
in	O
pregnant	O
women	I:C0033011
with	O
subclinical	O
and	O
overt	O
hypothyroidism	B:C0020676
until	O
large	O
scale	O
randomized	O
controlled	I:C0206035
trials	I:C0206035
are	O
performed	O
.	O

It	O
is	O
not	O
possible	O
to	O
unequivocally	O
advocate	O
for	O
thyroxine	O
replacement	O
in	O
pregnant	O
women	I:C0033011
with	O
subclinical	O
and	O
overt	O
hypothyroidism	O
until	O
large	O
scale	O
randomized	B:C0206035
controlled	I:C0206035
trials	I:C0206035
are	O
performed	O
.	O

